Department of Medicine, University of South Dakota Sanford School of Medicine, Sioux Falls, South Dakota, USA.
Avera McKennan University Hospital and Transplant Institute, Sioux Falls, South Dakota, USA.
Clin Transplant. 2021 Dec;35(12):e14479. doi: 10.1111/ctr.14479. Epub 2021 Sep 23.
Data are sparse on etiology specific outcomes on waitlist (WL) and post-transplant outcomes among patients with acute on chronic liver failure (ACLF).
In a retrospective cohort of 14,774 adults from United network for organ sharing (UNOS) database listed for Liver transplantation (LT) with cirrhosis and ACLF (January 2013-June 2019), 40% were due to alcohol-associated liver disease (ALD), followed by hepatitis C virus (HCV) at 20%, non-alcoholic steatohepatitis (19%), cryptogenic cirrhosis (7%), autoimmune hepatitis (5%), primary sclerosing cholangitis (PSC) at 3%, and 2% each for hepatitis B, primary biliary cholangitis (PBC), and metabolic etiology. Using competing risk analysis, cumulative risk of WL mortality was highest for PBC at 20.5% and lowest for PSC at 13.3%, P < .001. Compared with ALD as reference, WL mortality was higher for PBC (1.45 [1.16-1.82]), and similar for other etiologies, P < .001. Of this cohort, 9650 (65.3%) patients received LT, with 1-year. patient survival of 91.6% for PBC, worst for cryptogenic cirrhosis (89.5%) and best for PSC and ALD (93.4%), P < .001.
Among listed candidates with ACLF, those with PBC have highest WL mortality 1-year. post-transplant survival was excellent among recipients for PBC. If these findings are validated in prospective studies, liver disease etiology should be considered for LT selection among patients in ACLF.
关于慢性肝衰竭(ACLF)患者在等待移植(LT)期间和移植后的病因特异性结局的数据很少。
在 14774 名来自美国器官共享联合网络(UNOS)数据库的成年人队列中,他们因肝硬化和 ACLF 而被列入 LT 名单(2013 年 1 月至 2019 年 6 月),其中 40%是由于酒精相关性肝病(ALD),其次是丙型肝炎病毒(HCV)占 20%,非酒精性脂肪性肝炎(NASH)占 19%,隐源性肝硬化占 7%,自身免疫性肝炎占 5%,原发性硬化性胆管炎(PSC)占 3%,乙型肝炎、原发性胆汁性胆管炎(PBC)和代谢性病因各占 2%。使用竞争风险分析,PSC 的 WL 死亡率累积风险最低,为 13.3%,而 PBC 最高,为 20.5%,P<0.001。与 ALD 作为参考相比,PBC 的 WL 死亡率更高(1.45[1.16-1.82]),而其他病因的死亡率相似,P<0.001。在这一队列中,9650 名(65.3%)患者接受了 LT,1 年时患者生存率为 91.6%,PBC 最差(89.5%),PSC 和 ALD 最好(93.4%),P<0.001。
在列入 ACLF 名单的候选者中,PBC 患者的 WL 死亡率最高,1 年时移植后的生存率也最高。如果这些发现能在前瞻性研究中得到验证,那么在 ACLF 患者中选择 LT 时就应该考虑肝病的病因。